Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
N
Shared by NobleBlocks on Nov 1, 2020 • 12:00 AM UTC
Authors:
J.K. Litton
,
S.A. Hurvitz
,
L.A. Mina
Research Assistant
AI chat, annotations, notes & similar papers
Finding related papers...
Discussions
(0)
No comments yet
Be the first to share your thoughts!
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial | NobleBlocks
